

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 9, 2010 (March 9, 2010)

---

**Protalix BioTherapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

Florida  
(State or other jurisdiction  
of incorporation)

001-33357  
(Commission File Number)

65-0643773  
(IRS Employer  
Identification No.)

2 Snunit Street  
Science Park, POB 455  
Carmiel, Israel  
(Address of principal executive offices)

20100  
(Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 2(b)
  - ☐ Pre-commencement communications pursuant to Rule 4(c)
- 
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On March 9, 2010, Mr. Eli Hurvitz, Chairman of the Board of Directors of Protalix BioTherapeutics, Inc. (the “Company”), resigned from his position as Chairman and member of the Board of Directors of the Company in order to focus on recovering from a recently diagnosed illness. In connection with Mr. Hurvitz’s resignation, the Board of Directors unanimously appointed Mr. Zeev Bronfeld, a longstanding member of the Board of Directors, to serve as interim Chairman of the Board, effective immediately.

**Item 8.01. Other Events**

On March 9, 2010, the Company issued a press release announcing Mr. Hurvitz’s resignation from his position as Chairman and member of the Board of Directors of the Company and the unanimous appointment of Mr. Zeev Bronfeld to serve as interim Chairman. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated March 9, 2010.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **PROTALIX BIOTHERAPEUTICS, INC.**

Date: March 9, 2010

By: /s/ David Aviezer

Name: David Aviezer, Ph.D.

Title: President and  
Chief Executive Officer

**Protalix Appoints Mr. Zeev Bronfeld Interim Chairman of the Board of Directors**

CARMIEL, Israel, March 9 — Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that Mr. Eli Hurvitz is relinquishing his position as Chairman and member of the Board of Directors of the Company in order to focus on recovering from a recently diagnosed illness. The Company's Board of Directors has unanimously appointed Mr. Zeev Bronfeld, a longstanding member of the Board of Directors, to serve as interim Chairman of the Board, effective immediately.

"We are very thankful to have had Mr. Eli Hurvitz serve as our Chairman. He brought a wealth of knowledge and expertise to Protalix that helped to grow the Company from a private research company to a fully integrated biotechnology company," said Mr. Bronfeld. "On behalf of everyone at Protalix, we wish Eli a fast and full recovery and hope he returns to his position with Protalix quickly."

Mr. Bronfeld became the Company's first investor and director in 1996. As a seasoned healthcare investor, Mr. Bronfeld brings vast experience in management and value building of biotechnology companies to the Company. He is a co-founder of Biocell Ltd., an Israeli publicly traded biotechnology holding company and has served as its Chief Executive Officer since 1986. Mr. Bronfeld currently serves as a director of Biocell Ltd., D. Medical Industries Ltd., and Biomedix Incubator Ltd., all of which are publicly-traded on the Tel Aviv Stock Exchange. Mr. Bronfeld is also a director of Meitav Technological Incubator Ltd., Ecocycle Israel Ltd., Contipi Ltd., Nilimedix Ltd., G-Sense Ltd. and L.N. Innovative Technologies. Mr. Bronfeld holds a B.A. in Economics from the Hebrew University.

**About Protalix**

Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system. Protalix's ProCellEx™ presents a proprietary method for the expression of recombinant proteins that the Company believes will allow for the industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease. In August 2009, the FDA granted orphan drug status and fast track designation to taliglucerase alfa for the treatment of Gaucher disease and Protalix filed a rolling NDA submission with the FDA in December 2009. In November 2009, Protalix granted Pfizer Inc. exclusive, worldwide rights to develop and commercialize taliglucerase alfa for the treatment of Gaucher disease, except in Israel. Protalix retained the right to commercialize taliglucerase alfa in Israel.

**Safe Harbor Statement:**

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation

---

Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes and are valid only as of the date hereof. We disclaim any obligation to update this information except to the extent required by law.

**Investor Contact:**

Marcy Nanus  
The Trout Group, LLC  
Telephone: 646-378-2927  
Email: [mnanus@troutgroup.com](mailto:mnanus@troutgroup.com)

**Media Contact:**

Brad Miles  
BMC Communications Group, LLC  
Telephone: 212-477-9007 x17  
Email: [brad@bmccommunications.com](mailto:brad@bmccommunications.com)